Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial
View ORCID ProfileBenjamin A. Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, View ORCID ProfileTony Whitehouse, James Scriven, Dhruv Parekh, Madhu S. Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew P. Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip N. Newsome, Anna Rowe, Rowena Sharpe, David R. Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns on behalf of CATALYST investigators
doi: https://doi.org/10.1101/2021.06.02.21258204
Benjamin A. Fisher
1Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
2National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Tonny Veenith
4Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
5Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
Daniel Slade
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Charlotte Gaskell
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Matthew Rowland
6Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
Tony Whitehouse
4Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
5Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
James Scriven
7Department of Infectious Diseases, University Hospitals Birmingham NHS Trust, UK
8Institute of Microbiology and Infection, University of Birmingham, UK
Dhruv Parekh
4Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
5Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
9Department of Respiratory Medicine, University Hospitals Birmingham NHS Trust, UK
Madhu S. Balasubramaniam
10Department of Critical Care Medicine, Royal Bolton Hospital, Bolton, UK
Graham Cooke
11Department of Infectious Disease, Imperial College London, London, UK
Nick Morley
12Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
Zoe Gabriel
13Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Matthew P. Wise
14Department of Critical Care Medicine, University Hospital of Wales, Cardiff, UK
Joanna Porter
15Department of Respiratory Medicine, University College Hospital, London, UK
Helen McShane
16The Jenner Institute, University of Oxford, Oxford, UK
Ling-Pei Ho
17MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
18Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Philip N. Newsome
2National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
19Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
Anna Rowe
2National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Rowena Sharpe
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
David R. Thickett
5Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
9Department of Respiratory Medicine, University Hospitals Birmingham NHS Trust, UK
Julian Bion
4Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
5Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
Simon Gates
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Duncan Richards
20Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK
Pamela Kearns
2National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Posted June 09, 2021.
Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial
Benjamin A. Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu S. Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew P. Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip N. Newsome, Anna Rowe, Rowena Sharpe, David R. Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns
medRxiv 2021.06.02.21258204; doi: https://doi.org/10.1101/2021.06.02.21258204
Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial
Benjamin A. Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu S. Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew P. Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip N. Newsome, Anna Rowe, Rowena Sharpe, David R. Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns
medRxiv 2021.06.02.21258204; doi: https://doi.org/10.1101/2021.06.02.21258204
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2253)
- Dermatology (199)
- Emergency Medicine (368)
- Epidemiology (11542)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3539)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2283)
- Health Policy (909)
- Hematology (333)
- HIV/AIDS (741)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3322)
- Nursing (189)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (521)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (221)
- Palliative Medicine (66)
- Pathology (434)
- Pediatrics (997)
- Primary Care Research (398)
- Public and Global Health (5966)
- Radiology and Imaging (1213)
- Respiratory Medicine (806)
- Rheumatology (367)
- Sports Medicine (309)
- Surgery (383)
- Toxicology (50)
- Transplantation (169)
- Urology (142)